Stryker (SYK) AI Stock Analysis

17 Followers

Stryker

(XETRA:SYK)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified organic growthGrowth across both MedSurg and Neurotechnology and Orthopaedics demonstrates a broad revenue base rather than dependence on one product area. This diversification, supported by procedure-driven demand and international expansion, can improve resilience and sustain growth over the next several quarters.

Negative Factors

Hip and knee market slowdownSlower hip and knee procedure growth directly pressures one of Stryker’s important orthopaedic franchises. Affordability concerns, pre-authorization denials and regional softness may constrain volumes for several quarters, reducing the benefit of the company’s established implant and instrument positions.

Stryker (SYK) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 127.56B
Dividend Yield: 1.02%
Average Volume (3M): 715
Price to Earnings (P/E): 35.5
Beta (1Y): 0.45
Revenue Growth: 2.43%
EPS Growth: 17.47%
Country: Germany
Employees: 56,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Stryker Business Overview & Revenue Model

Company Description

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hip...

Stryker Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:5.21%|Next Earnings Date:Feb 01, 2027

Earnings Call SentimentNeutral

The call was cautiously constructive but balanced. Stryker reported solid sales growth, adjusted EPS growth, margin expansion, strong cash generation, healthy capital demand, product momentum and a broad innovation and M&A pipeline. However, these positives were offset by a meaningful hip and knee market slowdown, weaker-than-expected commercial execution, Peripheral Vascular supply constraints and reduced full-year guidance. Management expressed confidence in the long-term outlook but acknowledged continued near-term uncertainty.

Positive Updates

Solid Third-Quarter Organic Sales Growth

Third-quarter organic sales grew 7.7%, including 9.1% growth in MedSurg and Neurotechnology and 5.9% growth in Orthopaedics. Endoscopy and Ortho Tech delivered double-digit performances, while Medical delivered near double-digit growth.

Negative Updates

Overall Results Fell Short of Expectations

Management stated that, despite solid growth in several businesses, overall third-quarter results fell short of expectations.

Company Guidance

Stryker’s updated guidance anticipates a similar overall organic growth rate for the company in Q4 as achieved in Q3, when organic sales growth was 7.7%, assuming a continuation of the procedure environment observed this quarter and continued strong capital demand; the company expects full year organic net sales growth of 6.5% to 7% and adjusted net earnings per share of $14.80 to $14.90, adjusted other income and expense of approximately $400 million, and a full year effective tax rate in the range of 15.5% to 16%. For Q4, Stryker expects strong growth for Trauma and Extremities, Medical to perform well, Instruments to have strong performances, and Peripheral Vascular to be a little bit better underlying; for 2027, while it will not provide formal guidance until early next year, it expects to deliver growth at the high end of our markets.

Stryker Risk Analysis

Stryker disclosed 29 risk factors in its most recent earnings report. Stryker reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Stryker Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:SYK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	81Outperform	$134.26B	25.63	10.60%	2.73%	9.77%	12.28%
GMED	74Outperform	$11.69B	19.69	11.59%	―	19.74%	51.10%
SNN	69Neutral	$13.40B	20.93	12.25%	2.48%	5.26%	31.02%
ZBH	69Neutral	$21.01B	26.91	6.05%	0.90%	6.98%	-2.22%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	40Underperform	$1.15B	84.15	1.24%	―	0.84%	―

* Healthcare Sector Average

Performance Comparison

DE:SYK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:SYK	Stryker Corp	292.80	-9.56	-3.16%
IART	Integra Lifesciences	13.42	1.24	10.18%
MDT	Medtronic	101.80	12.11	13.51%
SNN	Smith & Nephew Snats	31.15	-1.35	-4.15%
ZBH	Zimmer Biomet Holdings	105.59	17.80	20.28%
GMED	Globus Medical	71.05	-15.31	-17.73%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Stryker AI Stock Analysis